Less than five months after its groundbreaking ceremony, Akeso's bay area science park (phase I) has entered its main construction stage. Project manager Chen Tianhua said the phase II project is being prepared and is expected to start construction this year.

The groundbreaking ceremony for the bay area science park, which is located on Ma'an Island, Tsuihang New District, was held on December 2, 2020. The science park covers an area of over 100,000 square meters, with a total investment of 2.5 billion yuan. It will be built in three phases, with production systems in accordance with GMP standards of China, the United States and the European Union.

Chen said that the biomedical science and technology innovation park will have world-class comprehensive scientific research and innovation capabilities after completion integrating R&D of innovative antibody drugs, production, and sales of chemical solutions and preparations.

"Local governments have provided strong support in the construction of the science park," said Chen. To promote the construction of key projects, the Tsuihang New District administrative committee sends special personnel to visit the construction sites every week to ensure that all support measures have been implemented, and provide help where needed.

Akeso Biopharma Inc is a biopharmaceutical company focused on the R&D, production and commercialization of innovative antibody drugs affordable to patients worldwide. It was established in Zhongshan's National Health Technology Park in 2012, and went public on the main board of Hong Kong in April 2020. It has conducted business in Zhongshan for more than 8 years and has become a pioneer in the innovation and development of China's biomedical industry.